home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

4.110 -0.020 (-0.48%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

3 Highly Rated Biotech Stocks to Buy for 300% Gains ↗

February 26, 2024

Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.

Via InvestorPlace

AbCellera Announces Resignation of Board Member

February 23, 2024

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at Upcoming Investor Conferences in March

February 22, 2024

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript ↗

February 20, 2024

ABCL earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Recap: AbCellera Biologics Q4 Earnings ↗

February 20, 2024

Via Benzinga

AbCellera Reports Full Year 2023 Business Results

February 20, 2024

From AbCellera Biologics Inc.

Via Business Wire

These 9 AI Stock Categories Performed From +18% To -4% Last Week ↗

February 19, 2024

A synopsis of the performances of each of the 9 different artificial intelligence stock categories last week, and YTD, along with a description of what makes up each category and the stocks included in...

Via Talk Markets

Topics Artificial Intelligence

AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics ↗

February 19, 2024

The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.

Via Talk Markets

Topics Artificial Intelligence

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

January 23, 2024

From AbCellera Biologics Inc.

Via Business Wire

Earnings Scheduled For February 20, 2024 ↗

February 20, 2024

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.

Via Benzinga

4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond ↗

January 16, 2024

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

Via The Motley Fool

3 Growth Stocks That Could Go Parabolic in 2024 ↗

January 15, 2024

These innovation-oriented companies could take flight this year.

Via The Motley Fool

AI-Focused Drug Discovery Stocks Index Up 26% In December ↗

December 29, 2023

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.

Via Talk Markets

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

December 20, 2023

From AbCellera Biologics Inc.

Via Business Wire

AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week ↗

December 17, 2023

A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.

Via Talk Markets

Topics Artificial Intelligence

AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗

December 16, 2023

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

Via InvestorPlace

Topics Artificial Intelligence

The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week ↗

December 11, 2023

If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to...

Via Talk Markets

Topics Artificial Intelligence

Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November ↗

December 06, 2023

The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.

Via Talk Markets

Topics Artificial Intelligence

AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

November 16, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

November 03, 2023

From AbCellera Biologics Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 03, 2023

Via Benzinga

AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript ↗

November 03, 2023

ABCL earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 02, 2023

Via Benzinga

AbCellera Reports Q3 2023 Business Results

November 02, 2023

From AbCellera Biologics Inc.

Via Business Wire

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

November 01, 2023

From AbCellera Biologics Inc.

Via Business Wire

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

November 01, 2023

Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader

From Prelude Therapeutics, Inc.; AbCellera

Via GlobeNewswire

AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

October 31, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

October 11, 2023

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Two T-Cell Engager Presentations at SITC 2023

September 27, 2023

From AbCellera Biologics Inc.

Via Business Wire

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com